

Iconovo receives patent protection for ICORES® in China

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the Chinese Patent Office intends to approve Iconovo's application for a patent for the inhalation platform ICORES®. ICORES® is already being used in several of Iconovo's customer projects, and this new patent strengthens the intellectual property rights, benefiting customers who will launch pharmaceutical products based on the company's unique inhaler in the future.

The Chinese Patent Office has issued a Notice of Allowance for a patent application related to ICORES®, which means that Iconovo will receive patent protection for the inhaler in China until 2040 after a series of administrative steps. ICORES® is already protected by patents in Europe (EPO), Sweden, India, Japan and the USA.

"The preliminary notification from the Chinese Patent Office strengthens our intellectual property rights in China and enhances the value of our product portfolio. China is a fast-growing market and already one of the largest pharmaceutical markets in the world. Reservoir inhalers are of particular interest in China where Turbuhaler® from AstraZeneca is successful and inhalers with many doses are popular," says Roger Lassing, Vice President of Business Development at Iconovo.

About ICORES

ICORES is a flexible multi-dose dry powder inhaler with feedback features developed by Iconovo. ICORES is a reservoir inhaler similar in handling to AstraZeneca's best-selling Turbuhaler®. It features two separate reservoirs which allow for simultaneous inhalation of two different formulations that makes it suitable for combination products. Its intuitive handling, exact dose counting, and clear inhalation feedback helps the patient to stay compliant with the treatment. ICORES is ready for commercial manufacturing making it the best alternative for pharmaceutical companies seeking a reservoir inhaler.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

[Iconovo receives patent protection for ICORES® in China](#)